Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
BackgroundOur study aimed to evaluate the safety and immunogenicity of the third (booster) dose of the COVID-19 vaccine for patients with endocrine-related cancers.MethodsThis observational study involved 94 breast cancer patients, 92 thyroid cancer patients, and 123 healthy individuals who had rece...
Main Authors: | Shanshan Han, Yuping Yang, Tingrui Wang, Rui Song, Daixing Hu, Mingli Peng, Zijing Lin, Qin Deng, Hong Ren, Jia Ming |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Public Health |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1086872/full |
Similar Items
-
Booster doses of an inactivated F genotype mumps vaccine enhance immunogenicity in mice
by: Seo Yeon Kim, et al.
Published: (2024-03-01) -
Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
by: Yunyun Yi, et al.
Published: (2023-05-01) -
A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
by: Zhengchao Lv, et al.
Published: (2023-11-01) -
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
by: Anna Giuliano, et al.
Published: (2023-07-01) -
Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer
by: Rui Song, et al.
Published: (2022-10-01)